And perhaps also another "potential" perspective to consider:
(i) Patient is presumed clear of infection from initial consultation (tele-health or in person) based on other products / existing approaches.
(ii) Condition of the patient deteriorates and they end up in an ER.
(ii) Doctor in the ER then rapidly diagnoses respiratory infection using ResApp and proper and prompt treatment is given (as expanding and implementing ResApp in emergency room settings was one of the many reasons for the recent CR...).
(iv) Medical industry (and consumers) realise (hopefully) the easiness and effectiveness of ResApp as a frontline diagnostic tool, thus avoiding timely, dangerous and avoidable misdiagnosis.
Just another perspective/scenario to consider....
- Forums
- ASX - By Stock
- RAP
- Dr Keating Email Interview
Dr Keating Email Interview, page-103
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)